Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Intellectual-Property-Rights"

19 News Found

Innovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in China
Diagnostic Center | December 28, 2023

Innovent Biologics, Xuanzhu collaborate on clinical trial for advanced solid tumors in China

Innovent will supply sintilimab for the collaborated clinical trial


Moderna sues Pfizer, BioNTech for mRNA patent infringement
News | August 28, 2022

Moderna sues Pfizer, BioNTech for mRNA patent infringement

Complaints to be filed in both United States and Germany alleging that Pfizer and BioNTech's COVID-19 vaccine Comirnaty unlawfully infringes patents Moderna filed between 2010 and 2016


Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen
News | August 15, 2022

Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen

All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied


Natco Pharma appoints Dr. Pavan Ganapati Bhat as Executive Director
People | August 10, 2022

Natco Pharma appoints Dr. Pavan Ganapati Bhat as Executive Director

He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years


Cariflex breaks ground on world's largest polyisoprene latex plant in Singapore
News | July 29, 2022

Cariflex breaks ground on world's largest polyisoprene latex plant in Singapore

Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments


India welcomes TRIPS waiver deal at WTO
News | June 21, 2022

India welcomes TRIPS waiver deal at WTO

TRIPS waiver for five years agreed in the recently concluded WTO will help countries manufacture COVID vaccines to deal with the pandemic


GeneQuantum Healthcare's two bioconjugate drugs approved for clinical trials in Australia
Biotech | May 16, 2022

GeneQuantum Healthcare's two bioconjugate drugs approved for clinical trials in Australia

They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights


Biocytogen signs RenMab/RenLite licensing agreement with BeiGene
Biotech | April 26, 2022

Biocytogen signs RenMab/RenLite licensing agreement with BeiGene

In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)


USFDA approves IND application for Allied’s cancer treatment
Biotech | January 24, 2022

USFDA approves IND application for Allied’s cancer treatment

APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types